Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales
Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER.
Novo Nordisk's medicine sales grew 7% this quarter, but the company expects slower or flat growth for all of 2026—though they're more hopeful now because their weight-loss and diabetes drugs are selling better than expected. When a company raises its outlook after bad news, it means the good stuff happening right now might stick around, so watch if those popular drugs keep selling well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.